Senescent cells — cells that have permanently stopped dividing but resist programmed death — accumulate with age and drive inflammation, tissue dysfunction, and age-related disease through their inflammatory secretory phenotype (SASP). Senolytics selectively eliminate these cells.
What Does the Research Say?
Animal studies clearing senescent cells have produced dramatic results: improved physical function, reduced frailty, extended lifespan by up to 35%, and reversal of age-related conditions including pulmonary fibrosis, osteoporosis, and cardiovascular disease. The most studied senolytic combination is dasatinib + quercetin (D+Q).
A landmark 2023 clinical trial in patients with Alzheimer’s disease found D+Q cleared peripheral senescent cells — a key translational milestone for the field. A 2019 Mayo Clinic trial in patients with idiopathic pulmonary fibrosis found 3 weeks of D+Q improved physical function across multiple measures. Natural senolytics quercetin and fisetin are under active investigation.
Key Findings
- Senescent cell clearance extends healthy lifespan by up to 35% in animal models
- Dasatinib + quercetin is the first senolytic combination tested in human clinical trials with positive results
- Natural senolytics (quercetin, fisetin) show promise in rodents and early human studies
- Intermittent pulsed dosing appears more effective than continuous low-dose administration
Practical Takeaway
Available senolytics (quercetin, fisetin) can be found as supplements. Research-aligned dosing uses a pulse approach — higher doses for 2 consecutive days per month — rather than daily supplementation. Dasatinib requires a prescription. View quercetin options: quercetin supplements.